(Circulation. 1999;99:216-223.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Reduction of Stroke Incidence After Myocardial Infarction With Pravastatin
The Cholesterol and Recurrent Events (CARE) Study
From the Section of Cardiology, Dartmouth-Hitchcock Medical Center, Lebanon, NH (J.F.P.); School of Public Health, University of Texas Health Science Center at Houston (B.R.D., L.A.M., L.B.P., L.M.S.); Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (F.M.S., M.A.P., E.B.); Montreal Heart Institute, Montreal, Quebec, Canada (J.L.R.); Division of Cardiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada (V.B.); Section of Cardiology, University of Manitoba Health Sciences Center, Winnipeg, Manitoba, Canada (T.E.C.); and Cardiology Division, University of Texas–Southwestern Medical Center at Dallas (J.R.).
Correspondence to Jonathan F. Plehn, MD, Section of Cardiology, Dartmouth-Hitchcock Medical Center, 1 Medical Center Dr, Lebanon, NH 03756. E-mail jonathan.f.plehn{at}hitchcock.org
Background—The role of lipid modification in stroke prevention is controversial, although increasing evidence suggests that HMG-CoA reductase inhibition may reduce cerebrovascular events in patients with prevalent coronary artery disease.
Methods and Results—To test the hypothesis that cholesterol reduction with pravastatin may reduce stroke incidence after myocardial infarction, we followed 4159 subjects with average total and LDL serum cholesterol levels (mean, 209 and 139 mg/dL, respectively) who had sustained an infarction an average of 10 months before study entry and who were randomized to pravastatin 40 mg/d or placebo in the Cholesterol and Recurrent Events (CARE) trial. Using prospectively defined criteria, we assessed the incidence of stroke, a prespecified secondary end point, and transient ischemic attack (TIA) over a median 5-year follow-up period. Patients were well matched for stroke risk factors and the use of antiplatelet agents (85% of subjects in each group). Compared with placebo, pravastatin lowered total serum cholesterol by 20%, LDL cholesterol by 32%, and triglycerides by 14% and raised HDL cholesterol by 5% over the course of the trial. A total of 128 strokes (52 on pravastatin, 76 on placebo) and 216 strokes or TIAs (92 on pravastatin, 124 on placebo) were observed, representing a 32% reduction (95% CI, 4% to 52%, P=0.03) in all-cause stroke and 27% reduction in stroke or TIA (95% CI, 4% to 44%, P=0.02). All categories of strokes were reduced, and treatment effect was similar when adjusted for age, sex, history of hypertension, cigarette smoking, diabetes, left ventricular ejection fraction, and baseline total, HDL, and LDL cholesterol and triglyceride levels. There was no increase in hemorrhagic stroke in patients on pravastatin compared with placebo (2 versus 6, respectively).
Conclusions—Pravastatin significantly reduced stroke and stroke or TIA incidence after myocardial infarction in patients with average serum cholesterol levels despite the high concurrent use of antiplatelet therapy.
Key Words: stroke • cholesterol • myocardial infarction • arteriosclerosis • lipids
This article has been cited by other articles:
 |
|
 |
|
  H. F. Elewa, A. Kozak, A. B. El-Remessy, R. F. Frye, M. H. Johnson, A. Ergul, and S. C. Fagan Early Atorvastatin Reduces Hemorrhage after Acute Cerebral Ischemia in Diabetic Rats J. Pharmacol. Exp. Ther., August 1, 2009; 330(2): 532 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kushiro, K. Mizuno, N. Nakaya, Y. Ohashi, N. Tajima, T. Teramoto, S. Uchiyama, H. Nakamura, and for the Management of Elevated Cholesterol in the Pravastatin for Cardiovascular Event Primary Prevention in Patients With Mild-to-Moderate Hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Hypertension, February 1, 2009; 53(2): 135 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein, P. Amarenco, M. LaMonte, S. Gilbert, M. Messig, A. Callahan, M. Hennerici, H. Sillesen, K. M. A. Welch, and on behalf of the SPARCL Investigators Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and Women: Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study Stroke, September 1, 2008; 39(9): 2444 - 2448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. I. Levy, J. Mocco, R. M. Samuelson, R. D. Ecker, B. S. Jahromi, and L. N. Hopkins Optimal treatment of carotid artery disease. J. Am. Coll. Cardiol., March 11, 2008; 51(10): 979 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D.I. Vergouwen, R. J. de Haan, M. Vermeulen, and Y. B.W.E.M. Roos Statin Treatment and the Occurrence of Hemorrhagic Stroke in Patients With a History of Cerebrovascular Disease Stroke, February 1, 2008; 39(2): 497 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Air and B. M. Kissela Diabetes, the Metabolic Syndrome, and Ischemic Stroke: Epidemiology and possible mechanisms Diabetes Care, December 1, 2007; 30(12): 3131 - 3140. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chaturvedi, T. N. Turan, M. J. Lynn, S. E. Kasner, J. Romano, G. Cotsonis, M. Frankel, M. I. Chimowitz, and For the WASID Study Group Risk factor status and vascular events in patients with symptomatic intracranial stenosis Neurology, November 27, 2007; 69(22): 2063 - 2068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Samuelson, J. Yamamoto, E. I. Levy, A. H. Siddiqui, and L. N. Hopkins The Argument to Support Broader Application of Extracranial Carotid Artery Stent Technology Circulation, October 2, 2007; 116(14): 1602 - 1610. [Full Text] [PDF]
|
|
|
|
|
|
J. Kitayama, F. M. Faraci, S. R. Lentz, and D. D. Heistad Cerebral Vascular Dysfunction During Hypercholesterolemia Stroke, July 1, 2007; 38(7): 2136 - 2141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. F. Ford and M. A. Farber Role of Endovascular Therapies in the Management of Diverse Thoracic Aortic Pathology Perspectives in Vascular Surgery and Endovascular Therapy, June 1, 2007; 19(2): 134 - 143. [Abstract] [PDF]
|
|
|
|
|
|
M. S. Dhamoon, W. Tai, B. Boden-Albala, T. Rundek, M. C. Paik, R. L. Sacco, and M. S.V. Elkind Risk of Myocardial Infarction or Vascular Death After First Ischemic Stroke: The Northern Manhattan Study Stroke, June 1, 2007; 38(6): 1752 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Fagan, H. F. Elewa, and D. J. Rychly Statin Therapy for Secondary Stroke Prevention: Evidence Catches Up to Practice Journal of Pharmacy Practice, April 1, 2007; 20(2): 117 - 122. [Abstract] [PDF]
|
|
|
|
|
|
V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions Circulation, December 19, 2006; 114(25): 2871 - 2891. [Full Text] [PDF]
|
|
|
|
|
|
D. D. Waters, J. C. LaRosa, P. Barter, J.-C. Fruchart, A. M. Gotto Jr, R. Carter, A. Breazna, J. J.P. Kastelein, and S. M. Grundy Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients With Stable Coronary Disease in the TNT (Treating to New Targets) Study J. Am. Coll. Cardiol., November 7, 2006; 48(9): 1793 - 1799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Pedersen The gap between theory and practice: what do the trials tell us? Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F10 - F16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Stroke Prevention by Aggressive Reduction in C High-Dose Atorvastatin after Stroke or Transient Ischemic Attack N. Engl. J. Med., August 10, 2006; 355(6): 549 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Bushnell, J. Griffin, L. K. Newby, L. B. Goldstein, K. W. Mahaffey, C. A. Graffagnino, R. A. Harrington, H. D. White, R. J. Simes, R. M. Califf, et al. Statin Use and Sex-Specific Stroke Outcomes in Patients With Vascular Disease Stroke, June 1, 2006; 37(6): 1427 - 1431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Robinson, B. Smith, N. Maheshwari, and H. Schrott Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?: A Meta-Regression Analysis J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1855 - 1862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Fletcher, K. Berra, P. Ades, L. T. Braun, L. E. Burke, J. L. Durstine, J. M. Fair, G. F. Fletcher, D. Goff, L. L. Hayman, et al. Managing Abnormal Blood Lipids: A Collaborative Approach Circulation, November 15, 2005; 112(20): 3184 - 3209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ranade, T. G. Kirchgessner, O. A. Iakoubova, J. J. Devlin, T. DelMonte, P. Vishnupad, L. Hui, Z. Tsuchihashi, F. M. Sacks, M. S. Sabatine, et al. Evaluation of the Paraoxonases as Candidate Genes for Stroke: Gln192Arg Polymorphism in the Paraoxonase 1 Gene Is Associated With Increased Risk of Stroke Stroke, November 1, 2005; 36(11): 2346 - 2350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S.V. Elkind, A. C. Flint, R. R. Sciacca, and R. L. Sacco Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality Neurology, July 26, 2005; 65(2): 253 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J.P. Kastelein The realities of dyslipidaemia: what do the studies tell us? Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F27 - F33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. G. Brown Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F34 - F40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chapman Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F56 - F62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Budaj, K. Flasinska, J. M. Gore, F. A. Anderson Jr, O. H. Dabbous, F. A. Spencer, R. J. Goldberg, K. A.A. Fox, and for the GRACE Investigators Magnitude of and Risk Factors for In-Hospital and Postdischarge Stroke in Patients With Acute Coronary Syndromes: Findings From a Global Registry of Acute Coronary Events Circulation, June 21, 2005; 111(24): 3242 - 3247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Manno, J. L. D. Atkinson, J. R. Fulgham, and E. F. M. Wijdicks Emerging Medical and Surgical Management Strategies in the Evaluation and Treatment of Intracerebral Hemorrhage Mayo Clin. Proc., March 1, 2005; 80(3): 420 - 433. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Drexel Modern intervention strategies for managing dyslipidaemia: the case for combination therapy The British Journal of Diabetes & Vascular Disease, January 1, 2005; 5(1_suppl): S17 - S23. [Abstract] [PDF]
|
|
|
|
|
|
M. Betancourt, R. B. Van Stavern, D. Share, P. Gardella, M. Martus, and S. Chaturvedi Are patients receiving maximal medical therapy following carotid endarterectomy? Neurology, December 14, 2004; 63(11): 2011 - 2015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Lazar Role of statin therapy in the coronary bypass patient Ann. Thorac. Surg., August 1, 2004; 78(2): 730 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.M.A. Welch Statins for the prevention of cerebrovascular disease: the rationale for robust intervention Eur. Heart J. Suppl., July 1, 2004; 6(suppl_C): C34 - C42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. E. Walsh and M. Pignone Drug Treatment of Hyperlipidemia in Women JAMA, May 12, 2004; 291(18): 2243 - 2252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Bushnell, L. K. Newby, L. B. Goldstein, F. Lin, K. Yaffe, and J. A. Simon Statin use and stroke outcomes in the Heart and Estrogen-Progestin Replacement Study (HERS) Neurology, March 23, 2004; 62(6): 968 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L Carswell, K. A Beard, M. M Chevrette, C. N Pardue, D. C Hess, and S. C Fagan Tracking Trends in Secondary Stroke Prevention Strategies Ann. Pharmacother., February 1, 2004; 38(2): 215 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Broderick William M. Feinberg Lecture: Stroke Therapy in the Year 2025: Burden, Breakthroughs, and Barriers to Progress Stroke, January 1, 2004; 35(1): 205 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Lindsberg and A. J. Grau Inflammation and Infections as Risk Factors for Ischemic Stroke Stroke, October 1, 2003; 34(10): 2518 - 2532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Suryadevara, S. G. Storey, W. S. Aronow, and C. Ahn Association of Abnormal Serum Lipids in Elderly Persons With Atherosclerotic Vascular Disease and Dementia, Atherosclerotic Vascular Disease Without Dementia, Dementia Without Atherosclerotic Vascular Disease, and No Dementia or Atherosclerotic Vascular Disease J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2003; 58(9): M859 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M McKenney Potential Nontraditional Applications of Statins Ann. Pharmacother., July 1, 2003; 37(7): 1063 - 1071. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. I. Feldman, L. J. Appel, G. M. Chertow, D. Cifelli, B. Cizman, J. Daugirdas, J. C. Fink, E. D. Franklin-Becker, A. S. Go, L. L. Hamm, et al. The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods J. Am. Soc. Nephrol., July 1, 2003; 14(90002): S148 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ghosh and W. S. Aronow Utilization of Lipid-Lowering Drugs in Elderly Persons With Increased Serum Low-Density Lipoprotein Cholesterol Associated With Coronary Artery Disease, Symptomatic Peripheral Arterial Disease, Prior Stroke, or Diabetes Mellitus Before and After an Educational Program on Dyslipidemia Treatment J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2003; 58(5): M432 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kaste Statins in Threatened Stroke Stroke, February 1, 2003; 34(2): 351 - 353. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Di Napoli, A.A. Taccardi, M. Oliver, and R. De Caterina Statins and stroke: evidence for cholesterol-independent effects Eur. Heart J., December 2, 2002; 23(24): 1908 - 1921. [PDF]
|
|
|
|
 |
|
 A. T Hirsch and A. M Gotto Jr Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction Vascular Medicine, November 1, 2002; 7(4): 323 - 331. [Abstract] [PDF]
|
|
|
|
|
|
W. S. Aronow, C. Ahn, and H. Gutstein Reduction of New Coronary Events and New Atherothrombotic Brain Infarction in Older Persons With Diabetes Mellitus, Prior Myocardial Infarction, and Serum Low-Density Lipoprotein Cholesterol >=125 mg/dl Treated With Statins J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2002; 57(11): M747 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Gotto Jr and J. A. Farmer Reducing the Risk for Stroke in Patients With Myocardial Infarction: A Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) Substudy Circulation, September 24, 2002; 106(13): 1595 - 1598. [Full Text] [PDF]
|
|
|
|
|
|
D. D. Waters, G. G. Schwartz, A. G. Olsson, A. Zeiher, M. F. Oliver, P. Ganz, M. Ezekowitz, B. R. Chaitman, S. J. Leslie, T. Stern, et al. Effects of Atorvastatin on Stroke in Patients With Unstable Angina or Non-Q-Wave Myocardial Infarction: A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Substudy Circulation, September 24, 2002; 106(13): 1690 - 1695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. Aronow Guest Editorial: Should Hypercholesterolemia in Older Persons Be Treated to Reduce Cardiovascular Events? J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2002; 57(7): M411 - 413. [Full Text]
|
|
|
|
|
|
M. S. Mouradian, S. R. Majumdar, A. Senthilselvan, K. Khan, and A. Shuaib How Well Are Hypertension, Hyperlipidemia, Diabetes, and Smoking Managed After a Stroke or Transient Ischemic Attack? Stroke, June 1, 2002; 33(6): 1656 - 1659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Loftus and M. Thompson The role of matrix metalloproteinases in vascular disease Vascular Medicine, May 1, 2002; 7(2): 117 - 133. [Abstract] [PDF]
|
|
|
|
|
|
B. G. Vickrey, T. S. Rector, S. L. Wickstrom, P. M. Guzy, E. M. Sloss, P. B. Gorelick, S. Garber, D. F. McCaffrey, M. D. Dake, and R. A. Levin Occurrence of Secondary Ischemic Events Among Persons With Atherosclerotic Vascular Disease Stroke, April 1, 2002; 33(4): 901 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Gorelick Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy: An Invited Review Stroke, March 1, 2002; 33(3): 862 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Kreisberg and A. Oberman Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 423 - 437. [Full Text] [PDF]
|
|
|
|
|
|
D. Tanne, N. Koren-Morag, E. Graff, and U. Goldbourt Blood Lipids and First-Ever Ischemic Stroke/Transient Ischemic Attack in the Bezafibrate Infarction Prevention (BIP) Registry: High Triglycerides Constitute an Independent Risk Factor Circulation, December 11, 2001; 104(24): 2892 - 2897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Amarenco Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction Neurology, September 1, 2001; 57(90002): S35 - 44. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. I. Qureshi, M. F. K. Suri, L. R. Guterman, and L. N. Hopkins Ineffective Secondary Prevention in Survivors of Cardiovascular Events in the US Population: Report From the Third National Health and Nutrition Examination Survey Arch Intern Med, July 9, 2001; 161(13): 1621 - 1628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bloomfield Rubins, J. Davenport, V. Babikian, L. M. Brass, D. Collins, L. Wexler, S. Wagner, V. Papademetriou, G. Rutan, and S. J. Robins Reduction in Stroke With Gemfibrozil in Men With Coronary Heart Disease and Low HDL Cholesterol : The Veterans Affairs HDL Intervention Trial (VA-HIT) Circulation, June 12, 2001; 103(23): 2828 - 2833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Statin therapy - what now? DTB, March 1, 2001; 39(3): 17 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. Aronow Treatment of Older Persons With Hypercholesterolemia With and Without Cardiovascular Disease J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2001; 56(3): 138M - 145. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Alberts Suppression of recurrent transient ischemic attacks by a statin agent Neurology, February 27, 2001; 56(4): 531 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Plutzky and P. M. Ridker Statins for Stroke: The Second Story? Circulation, January 23, 2001; 103(3): 348 - 350. [Full Text] [PDF]
|
|
|
|
|
|
R. P. Byington, B. R. Davis, J. F. Plehn, H. D. White, J. Baker, S. M. Cobbe, and J. Shepherd Reduction of Stroke Events With Pravastatin : The Prospective Pravastatin Pooling (PPP) Project Circulation, January 23, 2001; 103(3): 387 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Goldstein, R. Adams, K. Becker, C. D. Furberg, P. B. Gorelick, G. Hademenos, M. Hill, G. Howard, V. J. Howard, B. Jacobs, et al. Primary Prevention of Ischemic Stroke : A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association Circulation, January 2, 2001; 103(1): 163 - 182. [Full Text] [PDF]
|
|
|
|
|
|
L. B. Goldstein, R. Adams, K. Becker, C. D. Furberg, P. B. Gorelick, G. Hademenos, M. Hill, G. Howard, V. J. Howard, B. Jacobs, et al. Primary Prevention of Ischemic Stroke : A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association Stroke, January 1, 2001; 32(1): 280 - 299. [Full Text] [PDF]
|
|
|
|
|
|
A. S. Brett, J. F. Meilof, B. M.I. Uitdehaag, O. Fruchter, H. D. White, R. J. Simes, A. M. Tonkin, and The LIPID Study Group Pravastatin Therapy and the Risk of Stroke N. Engl. J. Med., December 21, 2000; 343(25): 1894 - 1896. [Full Text]
|
|
|
|
|
|
Z. Yang, T. Kozai, B. van de Loo, H. Viswambharan, M. Lachat, M. I. Turina, T. Malinski, and T. F. Luscher HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1691 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hsia, J. A. Simon, F. Lin, W. B. Applegate, M. T. Vogt, D. Hunninghake, and M. Carr Peripheral Arterial Disease in Randomized Trial of Estrogen With Progestin in Women With Coronary Heart Disease : The Heart and Estrogen/Progestin Replacement Study Circulation, October 31, 2000; 102(18): 2228 - 2232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. White, R. J. Simes, N. E. Anderson, G. J. Hankey, J. D.G. Watson, D. Hunt, D. M. Colquhoun, P. Glasziou, S. MacMahon, A. C. Kirby, et al. Pravastatin Therapy and the Risk of Stroke N. Engl. J. Med., August 3, 2000; 343(5): 317 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Wannamethee, A. G. Shaper, and S. Ebrahim HDL-Cholesterol, Total Cholesterol, and the Risk of Stroke in Middle-Aged British Men Stroke, August 1, 2000; 31(8): 1882 - 1888. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J F Albucher, J Ferrieres, J B Ruidavets, B Guiraud-Chaumeil, B P Perret, and F Chollet Serum lipids in young patients with ischaemic stroke: a case-control study J. Neurol. Neurosurg. Psychiatry, July 1, 2000; 69(1): 29 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Vauthey, G. R. de Freitas, G. van Melle, G. Devuyst, and J. Bogousslavsky Better outcome after stroke with higher serum cholesterol levels Neurology, May 23, 2000; 54(10): 1944 - 1949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Tunick, G. A. Krinsky, V. S. Lee, and I. Kronzon Diagnostic Imaging of Thoracic Aortic Atherosclerosis Am. J. Roentgenol., April 1, 2000; 174(4): 1119 - 1125. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Tunick and I. Kronzon Atheromas of the thoracic aorta: clinical and therapeutic update J. Am. Coll. Cardiol., March 1, 2000; 35(3): 545 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Hess, A. M. Demchuk, L. M. Brass, and F. M. Yatsu HMG-CoA reductase inhibitors (statins): A promising approach to stroke prevention Neurology, February 22, 2000; 54(4): 790 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F Oliver Cholesterol and strokes BMJ, February 19, 2000; 320(7233): 459 - 460. [Full Text]
|
|
|
|
 |
|
 B. Hsiang, Y. Zhu, Z. Wang, Y. Wu, V. Sasseville, W.-P. Yang, and T. G. Kirchgessner A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2). IDENTIFICATION OF A LIVER-SPECIFIC HUMAN ORGANIC ANION TRANSPORTING POLYPEPTIDE AND IDENTIFICATION OF RAT AND HUMAN HYDROXYMETHYLGLUTARYL-CoA REDUCTASE INHIBITOR TRANSPORTERS J. Biol. Chem., December 24, 1999; 274(52): 37161 - 37168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Demchuk, D. C. Hess, L. M. Brass, and F. M. Yatsu Is Cholesterol a Risk Factor for Stroke?: Yes Arch Neurol, December 1, 1999; 56(12): 1518 - 1520. [Full Text] [PDF]
|
|
|
|
|
|
C. R. Kumana, B. M. Y. Cheung, and I. J. Lauder Gauging the Impact of Statins Using Number Needed to Treat JAMA, November 24, 1999; 282(20): 1899 - 1901. [Full Text] [PDF]
|
|
|
|
|
|
E. R Mohler III, N. Delanty, D. J Rader, and E. C Raps Statins and cerebrovascular disease: plaque attack to prevent brain attack Vascular Medicine, November 1, 1999; 4(4): 269 - 272. [Abstract] [PDF]
|
|
|
|
|
|
R. Mantyla, H. J. Aronen, O. Salonen, T. Pohjasvaara, M. Korpelainen, T. Peltonen, C.-G. Standertskjold-Nordenstam, M. Kaste, and T. Erkinjuntti Magnetic Resonance Imaging White Matter Hyperintensities and Mechanism of Ischemic Stroke Stroke, October 1, 1999; 30(10): 2053 - 2058. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Pfefferkorn, H.-P. Knuppel, B. R. Jaeger, J. Thiery, and G. F. Hamann Increased Cerebral CO2 Reactivity After Heparin-Mediated Extracorporal LDL Precipitation (HELP) in Patients With Coronary Heart Disease and Hyperlipidemia Stroke, September 1, 1999; 30 (9): e1802 - 1806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Wolf, G. P. Clagett, J. D. Easton, L. B. Goldstein, P. B. Gorelick, M. Kelly-Hayes, R. L. Sacco, and J. P. Whisnant Preventing Ischemic Stroke in Patients With Prior Stroke and Transient Ischemic Attack : A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association Stroke, September 1, 1999; 30(9): 1991 - 1994. [Full Text] [PDF]
|
|
|
|
|
|
F. B. Hu, M. J. Stampfer, E. B. Rimm, J. E. Manson, A. Ascherio, G. A. Colditz, B. A. Rosner, D. Spiegelman, F. E. Speizer, F. M. Sacks, et al. A Prospective Study of Egg Consumption and Risk of Cardiovascular Disease in Men and Women JAMA, April 21, 1999; 281(15): 1387 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Pravastatin Reduces Stroke Too Journal Watch Cardiology, March 12, 1999; 1999(312): 1 - 1. [Full Text]
|
|
|
|
 |
|
 Reduction of Stroke Incidence with Pravastatin Journal Watch (General), February 2, 1999; 1999(202): 3 - 3. [Full Text]
|
|